Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - NOVARTIS PATIENT COUNSELLING

Novartis launches AMD patient counselling programme

Aurobindo Pharma HIV/AIDS drug lamivudine gets tentative US FDA nod

BY OUR PHARMA CORRESPONDENT

 

16 June, 2005: Novartis Pharmaceuticals Canada Inc has launched a nationwide education programme in Canada designed to generate awareness on the risk of Age-Related Macular Degeneration (AMD). AMD is a cause for severe vision loss and blindness in people aged over 50.

More than 2.1 million Canadians are currently affected by AMD, and one in five Canadians aged between 50 and 64 is at risk of developing AMD.

The patient-counselling programme, available at eye doctor's offices across Canada, helps facilitate dialogue between patients and doctors, fulfilling an unmet patient education need. The programme material includes eye doctor reference materials, educational posters detailing the physiology of the eye, and five comprehensive patient-friendly brochures.

These brochures help to better understand the disease, associated risk factors and treatment options for both dry and wet AMD, Novartis said in a release.

Developed in response to patient and doctor demand, the programme was created with the help of eye doctors. A panel of retina specialists, ophthalmologists and optometrists from across Canada reviewed and approved the program, the statement said.

Dr Patricia Harvey, retina specialist, University Health Network said: "The AMD Patient Counselling Programme is a welcomed - and much needed - tool for ocular health professionals and their patients. Both eye doctors and patients will be pleased with the quality and depth of the materials." 

"The programme will help ensure patients understand their disease. Thanks to this, doctors have detailed information and patients have easy-to-read materials. This is especially important as the Canadian population ages and cases of AMD are likely to rise."

In addition to the programme, Novartis has invested in raising awareness of AMD and to reinforce the need for early diagnosis through an advertising campaign entitled 'I wish I had known'.

The investment made by Novartis throughout 2004 is the first with respect to AMD awareness. John Snisarenko, Vice President, Novartis Pharmaceuticals Canada said, “early diagnosis is critical to preventing and treating AMD. Understanding the symptoms and reducing risk factors are integral steps to combating this disease”.
 

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

Viruses may help cure cancer by killing cancer cells

New product relieves tooth pain resulting from dental sensitivity 

Cervical Cancer detector may improve on Pap Smears

Dietary supplement capsule by Liqing banned in US

Cold Stone Creamery cake batter ice-creams recalled

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA approval for PEPFAR

Gates Foundation donates for a good cause

Paxil CR resupply in US pharmacies announced by GlaxoSmithKline

Viagra users not at risk of blindness: Pfizer

Stem cell research gets boost from Li Ka-shing

BiDil heart failure drug for black patients approved

Restless leg syndrome could be messing up your sleep

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

German Remedies launches Fludara Oral

Ranbaxy acquires generic product portfolio from Efarmes

Sandoz files seven ANDAs of drugs going off-patent

Elder Pharma plans unit, brand acquisition

Novasite Pharma buys PsyCheNomicS

Chemokine gets US patent for novel cancer drug

Roche gets USFDA approval for oral Xeloda

Nectar Lifesciences plans Rs 90 crore IPO 

Glaxo inks co-promotion pact with Eisai for Paritec

Early Intervention required to Prevent Diabetes

AIDS drug ahoy!

Novartis launches AMD patient counselling programme

Nanobac Life Sciences, UCSF to study kidney stones 

Surface Logix commences phase I trial for PDE-5 inhibitor

Temasek sets up $112 million pharma JV

Contraceptive from Neem, courtesy DRDO  

US FDA to source anti-HIV drugs from Indian firms  

Chemists boycott Glaxo, Novartis products  

Maharashtra phases out nerve tissue-based rabies vaccine  

Last long, really long - new sex drug soon  

Johnson and Johnson demonstrates coronary stent safety

Novartis has better breast cancer treatment

Pfizer's investigational drug reduces tumor growth

New labeling for beta-blocker Coreg 

Glaxo applies for FDA approval for Flaurix

Investigational drug for Acute Bipolar Mania And Schizophrenia

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us